The difficulty lies in the biological complexity and many pathways at play in chronic conditions like heart failure. They exhibit a variety of symptoms and comorbidities over time, and they are heterogeneous both in their presentation and in how they are identified as the disease progresses.
There are numerous underlying causes of heart failure, which affects 64 million individuals globally. There is now a “one-size-fits-all” strategy to treating heart failure. Yet this isn’t always the best course of action because there are so many different ways that heart failure can manifest itself.
Nowadays, diagnosis is based on clinical symptoms and accepted biomarkers, which are traits of the patient like a gene, molecule, or something else (like blood pressure). Nevertheless, tests are frequently constrained, imprecise, and performed late in the course of the disease.
Signs And Symptoms Of Heart Failure
AstraZeneca’s goal is to decipher the intricate disease biology of heart failure at the molecular level in each patient by utilizing artificial intelligence, machine learning, and gene expression analysis.
Inspiration can occasionally appear out of the blue. For the purpose of managing enormous data sets derived from the financial sector, Anna Reznichenko, Senior Principal Scientist, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, has developed a revolutionary method based on market segmentation analysis.
Using AI To Find New Targets
We can discover unique links between data and disease by merging rich data sets, including patient data, and using AI and machine learning. With the help of BenevolentAI, AstraZeneca is analyzing enormous volumes of scientific data to determine any possible connections between disease, gene targets, and expression.
The partnership combines BenevolentAI’s knowledge graph and machine learning techniques with AstraZeneca’s medical expertise to find unique insights and correlations that reveal new hypotheses and suggest medication targets for diseases that have never been thought of before.
The cooperation between the two businesses has led to the effective identification of possible new targets in idiopathic pulmonary fibrosis and chronic renal disease. The team is now experimentally verifying potential targets for heart failure
